Home/Clinical Trials
RecruitingPhase 3CT-2026-101
Emzaratinib after surgery in early-stage lung cancer
Non-small cell lung cancer · Oncology
Ages 18 years and older740 participantsChicago, IL, London, UK +2 more
RecruitingPhase 3CT-2023-112
Subcutaneous trelanemab in early Alzheimer's disease
Alzheimer's disease · Neuroscience
Ages 50 to 85 years950 participantsChicago, IL, Berlin, Germany
RecruitingPhase 3CT-2024-111
Solekizumab in children with plaque psoriasis
Plaque psoriasis · Immunology
Ages 4 to 17 years1,230 participantsBerlin, Germany, Boston, MA
RecruitingPhase 3CT-2023-116
Once-weekly lorvatide in adults with obesity
Obesity · Cardiometabolic
Ages 18 years and older730 participantsBoston, MA, San Diego, CA +3 more
RecruitingPhase 3CT-2026-105
Tazulimab-cvra in newly diagnosed multiple myeloma
Multiple myeloma · Oncology
Ages 18 years and older1,120 participantsToronto, Canada, Raleigh, NC +1 more
Active, not recruitingPhase 3CT-2024-115
Long-term extension of trelanemab
Alzheimer's disease · Neuroscience
Ages 50 to 85 years1,600 participantsBerlin, Germany, Seoul, South Korea
Active, not recruitingPhase 3CT-2026-117
Semavotide in obesity with type 2 diabetes
Obesity · Cardiometabolic
Ages 18 to 80 years1,130 participantsMadrid, Spain, Raleigh, NC +1 more
Active, not recruitingPhase 3CT-2024-123
Elvoparvec 15-year follow-up registry
Spinal muscular atrophy · Rare Disease
Ages 18 to 75 years2,140 participantsSydney, Australia, Boston, MA +2 more
Active, not recruitingPhase 3CT-2024-107
Corvatinib in moderate-to-severe Crohn's disease
Crohn's disease · Immunology
Ages 18 to 75 years1,910 participantsMadrid, Spain, Berlin, Germany +2 more
Active, not recruitingPhase 3CT-2023-120
Calvasiran cardiovascular outcomes study
Hyperlipidemia · Cardiometabolic
Ages 18 years and older2,940 participantsSan Diego, CA, Madrid, Spain
Active, not recruitingPhase 3CT-2026-113
CLV-310 in early Parkinson's disease
Parkinson's disease · Neuroscience
Ages 50 to 85 years2,280 participantsToronto, Canada, Seoul, South Korea +3 more
CompletedPhase 3CT-2023-104
Berolumab-cvra versus chemotherapy in HER-low breast cancer
Breast cancer · Oncology
Ages 18 years and older2,030 participantsHouston, TX, London, UK +1 more
CompletedPhase 3CT-2025-110
Teravolumab in hidradenitis suppurativa
Hidradenitis suppurativa · Immunology
Ages 18 to 75 years3,000 participantsSeoul, South Korea, Tokyo, Japan +2 more
CompletedPhase 3CT-2025-130
Solekizumab every-12-weeks dosing study
Plaque psoriasis · Immunology
Ages 18 to 80 years2,680 participantsMadrid, Spain, London, UK +2 more
CompletedPhase 3CT-2023-124
Emzaratinib plus chemotherapy in metastatic lung cancer
Non-small cell lung cancer · Oncology
Ages 18 years and older1,120 participantsToronto, Canada, Raleigh, NC +2 more
Study listings are fictional. Talk with your doctor before joining any clinical trial.